At a major pharmacy meeting in March, experts mapped how fast GLP-1s are evolving, from a new oral pill to next-gen pills awaiting approval, and what that means for the people taking them.
At the American Pharmacists Association 2026 meeting in March, experts surveyed a fast-changing GLP-1 landscape: the oral Wegovy pill (oral semaglutide 25 mg), available since January with about 13.6 percent average weight loss in trials, and the near-approval oral, non-peptide orforglipron. The class is moving quickly from injections toward pills and new uses.
March is conference season for pharmacy too, and the GLP-1 story dominated.
An APhA 2026 session offered a clear status check on how fast the category is evolving.
Presenters reviewed newly available and near-approval GLP-1 agents. The oral Wegovy pill (oral semaglutide 25 mg), available since January 2026, was highlighted as a formulation advance using absorption-enhancing technology to overcome the bioavailability problems of earlier oral peptides; in its pivotal trial it delivered about 13.6 percent mean weight loss, with roughly 79 percent of participants achieving at least 5 percent weight loss versus about 31 percent on placebo. Experts also flagged orforglipron, a first-in-class oral, small-molecule, non-peptide GLP-1 awaiting FDA action, as a particularly important agent to watch.
The broader message was that GLP-1s are rewriting metabolic medicine, expanding from injections to pills, from diabetes and weight to a widening set of conditions, and reshaping how clinicians and pharmacists counsel patients. With that expansion comes complexity: more products, more formulations, and more nuance in matching a medicine to a person.
For consumers, the practical signal is more options and faster change, which makes professional guidance more valuable, not less. Oral options lower a barrier for needle-averse patients, but suitability, dosing, side effects, and cost still vary by individual and product. Trial figures describe averages in studied populations, not guarantees, and decisions belong with a licensed prescriber and, often, a pharmacist.
Key near-term watch items include the FDA decision on orforglipron and how oral options reshape prescribing and access. Expect continued counseling emphasis on side-effect management and adherence as more patients start therapy. For individuals, the durable approach is to treat conference and pipeline news as context for a conversation with a prescriber rather than a self-directed shopping list, and to verify that any product obtained is FDA-approved and lawfully dispensed.